StreetInsider.com News Articles

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Tue, 14 Jul 2026 07:02:00 -0400

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –

– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –

– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –

– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –

SAN

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 03 Jul 2026 07:30:00 -0400

SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five (5) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 03 Jul 2026 07:30:00 -0400

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 03 Jul 2026 07:30:00 -0400

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 03 Jul 2026 07:30:00 -0400

Form 4 Kura Oncology, Inc. For: Jun 18 Filed by: Leoni Mollie

Mon, 22 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26674322.html

Form 4 Kura Oncology, Inc. For: Jun 18 Filed by: Leoni Mollie

Mon, 22 Jun 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26674322.html

Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie

Thu, 18 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260618/26666395.html

Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie

Thu, 18 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260618/26666395.html

Kura Oncology (KURA) Reiterated at Market Outperform by Citizens After Data Presentation

Mon, 15 Jun 2026 05:13:15 -0400

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

The analyst commented, "We reiterate our Market Outperform rating and $24 price target for Kura Oncology based on a discounted EPS and revenue multiple analysis. Recently at EHA, Kura and partner, Kyowa Kirin, presented updated KOMET-007 data evaluating zifto + 7+3 in 1L NPM1-m and KMT2A-r AML, expanding the dataset to 99 patients (vs. 71 at EHA 2025). The EHA 2026 update shifted the narrative from depth to duration, with median CRc duration not reached in NPM1-m, 12.0 months in KMT2A-r and

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology Inc. (NASDAQ: KURA) and Kyowa Kirin Co. Ltd. (TSE: 4151) reported long-term results from their Phase 1/2 KOMET-007 trial testing ziftomenib combined with intensive chemotherapy in newly diagnosed acute myeloid leukemia patients.

The single-arm trial showed a 12-month overall survival rate of 94% among NPM1-mutant AML patients and 71% among KMT2A-rearranged AML patients. The companies reported 96% composite complete remission rates in NPM1-mutant AML patients and 90% in KMT2A-rearranged AML patients.

Median overall survival was not reached in either patient population, with median follow-up of 17.6 months for NPM1-mutant patients and 11.0 months for KMT2A-rearranged patients. The trial included 49

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology reports positive long-term cancer drug trial data

Thu, 11 Jun 2026 08:03:16 -0400

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Thu, 11 Jun 2026 08:02:00 -0400

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –

– 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML –

– High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing –

– Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively –

– 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare